Physician profile
Nilar U
NPI 1760416069
$11,699.33
in general payments reported to CMS, 2019-2025
45 companies · $1,507 in 2025
The $1,507 reported for 2025 was more than what 95% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,600 · 2020: $1,569 · 2021: $1,877 · 2022: $1,584 · 2023: $1,822 · 2024: $1,741 · 2025: $1,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,069.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,189.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,130.29 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,038.40 | 2019-2025 | Ubrelvy, Synthroid, Qulipta |
| Novo Nordisk INC | $849.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $825.39 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $810.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $717.64 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $558.53 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $517.95 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
| Amarin Pharma, INC. | $368.56 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.97 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $338.64 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $329.62 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Grifols USA, LLC | $326.57 | 2019-2023 | Prolastin-C Liquid |
| Esperion Therapeutics, INC. | $286.61 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilar U listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.